This study is testing a new therapy called GRIEF Approach (Grief Recovery with Individualized Evidence-Based Formulation) to help adults who have lost a loved one to a sudden or violent death, such as suicide, homicide, drug overdose, or car crash. Many people who experience this type of loss develop depression, post-traumatic stress, and/or prolonged grief, and current treatments often fail to address all of these symptoms together. GRIEF Approach is a flexible, individualized therapy that combines evidence-based strategies to address traumatic stress, grief, and depression within a single treatment. The primary goal of this study is not to test whether the therapy works, but to evaluate whether it is feasible and acceptable to patients and therapists. Participants will complete mood and symptom questionnaires at the start of the study, weekly during treatment, and one month after treatment ends. Participants will also provide feedback on their experience with the therapy through questionnaires and brief interviews. Findings from this study will be used to refine the treatment and study procedures in preparation for a larger clinical trial.

This research study aims to better understand how the brain and body change during physical or occupational therapy after a neurologic injury or condition. Adults who are already receiving outpatient neurorehabilitation will be invited to participate while they complete their regular therapy sessions. During therapy, participants will wear a lightweight cap that measures brain activity and will be video recorded so researchers can analyze movement patterns using computer software. These recordings do not change therapy activities and are for research purposes only. The study does not involve new treatments, medications, or procedures beyond standard care. Information collected may help researchers understand why recovery differs between individuals and improve future rehabilitation approaches.

This study is designed to explore a new treatment option for motor symptoms in people with Parkinson's disease. Motor symptoms and gait disturbance for Parkinson's are often disabling and can increase risk of falls and requce quality of life. We are testing whether a non-invasive brain stimulation technique called transcutaneous auricular vagus nerve stimulation (taVNS) is tolerable, acceptable and can be administered at-home and used to improve symptoms of Parkinson's disease. TaVNS delivers electrical impulses through the skin of the ear to the vagus nerve which research has shown modulates brain activity. The purpose of this research is to see whether this treatment approach is feasible, tolerable and and potentially effective at treating the symptoms of Parkinson's disease. If successful, this research study will hopefully lead to a larger study in the future where the efficacy of the treatments can be studied.

Patients are matched with this clinical trial based on their biomarker test results in the myeloMATCH study. This treatment trial is for adults (ages 18-59) with high-risk AML who have not started treatment yet. Doctors consider AML high risk if it has certain biomarkers that can make it harder to treat. Treatment plans for AML often involve several phases of treatment. The first phase aims to get rid of as many leukemia cells as possible. It helps make it easier for further treatment to keep the cancer under control. Usually, the first treatment patients receive for AML is a combination of 2 chemotherapy drugs, daunorubicin and cytarabine. The purpose of this study is to learn if other options for first treatment may work better for people with high-risk AML. The study doctors will test 4 new treatments and compare them to the usual chemotherapy. This is important because knowing AML is high-risk gives doctors more information about the cancer and how to treat it. People with high-risk AML may benefit from a different approach to treatment. Improving options for people in the first phase of treatment could make further phases of treatment more successful.